A new oral tablet called daraxonrasib nearly doubled the overall survival of patients with metastatic pancreatic cancer in a U.S. Phase 2 clinical trial [1, 2].

This development represents a significant shift in treating one of the deadliest forms of cancer. Because the drug targets a specific genetic mutation that drives the vast majority of these tumors, it offers a potential lifeline for patients who have exhausted standard treatment options [1, 2].

Results reported in April 2026 showed that patients taking the medication experienced a median overall survival of 13.2 months [1]. In comparison, those receiving standard chemotherapy saw a median survival of 6.7 months [1].

"Daraxonrasib demonstrated a median overall survival of 13.2 months, nearly double the 6.7 months observed with standard chemotherapy," Dr. Michael Smith, Chief Medical Officer of Revolution Medicines, said [1].

The drug, developed by Revolution Medicines Inc., targets the KRAS mutation. This mutation is present in more than 90% of pancreatic cancers [2]. For years, the KRAS protein was considered undruggable by scientists, which limited the available therapeutic approaches for this disease [2].

Patient administration involves a single tablet taken once daily [2]. This oral delivery method simplifies the treatment process compared to traditional intravenous chemotherapy [2].

"For the first time we have an oral agent that can penetrate the KRAS‑driven pancreatic tumor and extend patients' lives," Dr. Ana Pereira, lead investigator at the Institute of Oncology, said [2].

Despite this progress, the disease remains extremely aggressive. The G1 editorial team noted that pancreatic cancer continues to be one of the deadliest cancers, with a five-year survival rate below 10% [3].

“Daraxonrasib demonstrated a median overall survival of 13.2 months, nearly double the 6.7 months observed with standard chemotherapy.”

The success of daraxonrasib validates a new pharmacological approach to targeting the KRAS mutation, which has long been a primary obstacle in oncology. By shifting from broad chemotherapy to a targeted oral therapy, clinicians may be able to improve patient quality of life while extending survival. However, as a Phase 2 trial, larger studies are required to confirm these results before the drug becomes a standard of care.